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1. INTRODUCTION {#acel12964-sec-0001}
===============

Much has been learned about the genetic basis of Alzheimer disease (AD), the most common cause of dementia in the elderly. Genome‐wide association studies (GWAS) have identified common and rare variants in more than 30 loci that contribute to AD risk (Bellenguez et al., [2017](#acel12964-bib-0003){ref-type="ref"}; Hollingworth et al., [2011](#acel12964-bib-0014){ref-type="ref"}; Jakobsdottir et al., [2016](#acel12964-bib-0016){ref-type="ref"}; Jun et al., [2017](#acel12964-bib-0018){ref-type="ref"}, [2016](#acel12964-bib-0019){ref-type="ref"}; Lambert et al., [2013](#acel12964-bib-0021){ref-type="ref"}; Mez et al., [2017](#acel12964-bib-0028){ref-type="ref"}; Naj et al., [2011](#acel12964-bib-0030){ref-type="ref"}; Sims et al., [2017](#acel12964-bib-0035){ref-type="ref"}). However, these associations explain only a fraction of the heritability of AD, and their functional consequence also remains unclear (Lambert et al., [2013](#acel12964-bib-0021){ref-type="ref"}; Ridge, Mukherjee, Crane, & Kauwe, [2013](#acel12964-bib-0033){ref-type="ref"}). Thus, here we investigate AD risk from a different perspective.

Epigenetic phenomena such as DNA methylation may be involved but have not been studied extensively in AD. DNA methylation is intimately associated with genetic variation because of frequent attachment of a methyl group directly to a DNA nucleotide, particularly a dinucleotide comprising a cytosine and guanine (CpG). CpG‐related SNPs (CGS) alter the sequence of the primary target sites for DNA methylation (Lister et al., [2009](#acel12964-bib-0025){ref-type="ref"}) and account for a significant fraction (\~38%--88%) of allele‐specific methylation (ASM) regions in the human genome (Shoemaker, Deng, Wang, & Zhang, [2010](#acel12964-bib-0034){ref-type="ref"}). It has been demonstrated that more than 80% of CGSes have a regulatory role in DNA methylation (Zhi et al., [2013](#acel12964-bib-0042){ref-type="ref"}). Recently, we found that a haplotype of multiple CGSes is associated with DNA methylation patterns on a genome‐wide scale (Ma et al., [2016](#acel12964-bib-0026){ref-type="ref"}). DNA methylation has been shown to influence risk of age‐related diseases (Hunter et al., [2012](#acel12964-bib-0015){ref-type="ref"}; De Jager et al., [2014](#acel12964-bib-0007){ref-type="ref"}). For example, a genome‐wide DNA methylation study reported association of AD pathological features with methylation changes at several loci (De Jager et al., [2014](#acel12964-bib-0007){ref-type="ref"}). Also, levels of DNA methylation of *GSTM1* and *GSTM5* have been associated with risk of age‐related macular degeneration (Hunter et al., [2012](#acel12964-bib-0015){ref-type="ref"}).

In this study, we evaluated the association of AD with CGSes genome‐wide and validated significant findings by expression quantitative trait locus (eQTL) and methylation QTL (mQTL) analyses.

2. RESULTS {#acel12964-sec-0002}
==========

2.1. Sliding Window Association of CGSes with AD {#acel12964-sec-0003}
------------------------------------------------

Association of AD with CGSes was tested genome‐wide using sliding windows that were 1 kb in length, overlapping by 0.5 kb and contained at least two CGSes. These analyses, which were performed using SKAT‐O (Lee, Wu, & Lin, [2012](#acel12964-bib-0022){ref-type="ref"}), considered the combined effects of all CGSes in a window and weighted rare variants more heavily than common variants. Because the SKAT‐O window‐based test does not consider the effect direction of the variants in each window, we also tested a model including CGS dosage which was calculated as the total number of CpG dinucleotides created by the CGSes in the window. Genome‐wide analysis of 2,288,371 overlapping windows each containing at least two CGSes showed little evidence of inflation (λ = 1.099, Figure [S1](#acel12964-sup-0001){ref-type="supplementary-material"}). SKAT‐O and CGS dosage approaches provided similar results across the genome (Figure [S2](#acel12964-sup-0001){ref-type="supplementary-material"}) including five distinct genome‐wide significant loci with windows at *BIN1* (SKAT‐O *p* = 1.27 × 10^−13^, CGS dosage *p* = 4.74 × 10^−18^), *MS4A6A* (SKAT‐O *p* = 2.66 × 10^−10^, CGS dosage *p* = 3.40 × 10^−10^), *MS4A4A* (SKAT‐O *p* = 6.36 × 10^−10^, CGS dosage *p* = 2.67 × 10^−10^), *PICALM* (SKAT‐O *p* = 6.34 × 10^−9^, CGS dosage *p* = 1.42 × 10^−9^), and *APOE* (SKAT‐O *p* = 2.99 × 10^−46^, CGS dosage *p* = 2.77 × 10^−556^) (Table [1](#acel12964-tbl-0001){ref-type="table"}). Although the top windows at *BIN1* and *PICALM* identified by SKAT‐O do not reach genome‐wide significance in the CGS dosage test, the CGS dosage test identified significant associations with other windows at these loci. Windows at *LRFN2‐UNC5CL* and *TREM2* are genome‐wide significant with only the SKAT‐O test, whereas the windows at *CR1* are genome‐wide significant with only the CGS dosage test. All genome‐wide significant windows identified by SKAT‐O were replicated (Table [2](#acel12964-tbl-0002){ref-type="table"}).

###### 

Top‐ranked windows associated with AD by SKAT‐O and CG dosage methodologies in discovery stage

  Chr                                     Gene           Start         End           *N* of CGSes   P range of CGSes (min, max)   Window P[a](#acel12964-note-0003){ref-type="fn"}   Window P[b](#acel12964-note-0004){ref-type="fn"}   Beta (*SE*)
  --------------------------------------- -------------- ------------- ------------- -------------- ----------------------------- -------------------------------------------------- -------------------------------------------------- ---------------
  Common loci identified by two methods                                                                                                                                                                                                 
  2                                       BIN1           127,847,001   127,848,000   2              (1.48E−13, 5.88E−06)          1.27E−13                                           2.14E−03                                           −0.02 (0.005)
  2                                       BIN1           127,881,001   127,882,000   2              (2.5E−12, 3.67E−03)           1.09E−03                                           4.74E−18                                           0.18 (0.02)
  11                                      MS4A6A         59,923,001    59,924,000    2              (1.41E−10, 1.25E−09)          2.66E−10                                           3.40E−10                                           −0.01 (0.002)
  11                                      MS4A4A         60,087,501    60,088,500    2              (8.44E−12, 1.23E−05)          6.36E−10                                           2.67E−10                                           −0.02 (0.003)
  11                                      PICALM         85,759,501    85,760,500    2              (3.77E−05, 0.11)              6.34E−09                                           9.28E−05                                           0.01 (0.002)
  11                                      PICALM         85,845,001    85,846,000    2              (3.77E−05, 0.11)              5.10E−02                                           1.42E−09                                           0.13 (0.02)
  19                                      APOE           45,411,501    45,412,500    2              (\<2.23e−308, 3.56E−28)       2.99E−46                                           2.77E−556                                          0.2 (0.004)
  Top loci identified by either method                                                                                                                                                                                                  
  1                                       CR1            207,737,501   207,738,500   3              (1.49E−10, 0.06)              7.01E−04                                           8.57E−11                                           −0.15 (0.02)
  6                                       LRFN2‐UNC5CL   40,825,501    40,826,500    3              (1.38E−06, 0.90)              1.21E−08                                           8.00E−02                                           −0.01 (0.005)
  6                                       TREM2          41,128,501    41,129,500    5              (1.34E−06, 0.92)              1.73E−08                                           6.80E−06                                           −0.08 (0.002)

P values obtained by SKAT‐O test.

P values obtained by CGSes dosage test and beta represent the change in log odds of AD per 1‐unit increase in dosage of CpG dinucleotides comprising the CpG‐related SNPs in the window.
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###### 

Top‐ranked windows associated with AD in replication stage

  Window   Chr   Start         End           Region or closest gene   *N* of CGSes   Top CGS in the window   Discovery stage   Replication stage                                                                                  
  -------- ----- ------------- ------------- ------------------------ -------------- ----------------------- ----------------- ------------------- ---------- ------------------- ------------- ------------- ------------------- -----------
  1        2     127,847,001   127,848,000   *BIN1*                   2              rs35114168              A                 0.39                1.27E−13   1.16 (1.12, 1.21)   1.48E−13      2.96E−07      1.13 (1.08, 1.18)   2.96E−07
  2        11    59,923,001    59,924,000    *MS4A6A*                 2              rs983392                G                 0.39                2.66E−10   0.88 (0.85, 0.91)   1.41E−10      2.83E−05      0.91 (0.87, 0.95)   2.53E−05
  3        11    60,087,501    60,088,500    *MS4A4A/MS4A6E*          2              rs4354705               C                 0.36                6.36E−10   0.87 (0.83, 0.90)   8.44E−12      6.93E−03      0.94 (0.90, 0.98)   3.97E−03
  4        11    85,759,501    85,760,500    *PICALM*                 2              rs694011                T                 0.32                6.34E−09   0.90 (0.86, 0.95)   3.77E−05      1.65E−05      0.90 (0.86, 0.94)   9.30E−06
  5        19    45,411,501    45,412,500    *APOE*                   2              rs429358                C                 0.25                2.99E−46   3.73 (3.53, 3.94)   \<2.23E−308   \<2.23E−308   3.47 (3.26, 3.69)   1.09E−345
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Windows in *MS4A4A* and *MS4A6A* showed a strong negative dosage effect of CpG dinucleotides on AD risk (change in log odds of AD = −0.01 and −0.02 per one unit dinucleotide increase, *p* = 2.67 × 10^−10^ and 3.4 × 10^−10^, respectively). This effect was evident in 18 out of 24 cohorts (Figure [1](#acel12964-fig-0001){ref-type="fig"}). The dosage of CpG dinucleotides created by the two CGSes in the *APOE* window has significantly positive association with AD risk (change in log odds of AD = 0.2 per one unit dinucleotide increase, *p* = 2.77 × 10^−556^).

![Forest plot of dose--response effect of the number of CpG dinucleotides created by the CGSes in the intergenic window close to *MS4A4A* on the logged odds ratio of AD. The filled square and horizontal line for each population or the filled diamond for the summary denote the estimated logged odds ratio and its 95% CI per unit increase in the number of CpG dinucleotides in the window](ACEL-18-e12964-g001){#acel12964-fig-0001}

In order to show the unique role of CGSes in these windows, we compared the significance level for the windows under two conditions, (a) including only CGSes and (b) including only non‐CGSes, which are the SNPs that do not disrupt CpG dinucleotide formation. As shown in Table [3](#acel12964-tbl-0003){ref-type="table"}, the *p* values of all the identified AD‐associated windows in Table [1](#acel12964-tbl-0001){ref-type="table"} were attenuated when only non‐CGSes were included in the test. The number of CGSes and non‐CGSes in each top window differed by no more than two except for the windows at *MS4A4A* and *PICALM*. There is very modest LD between the top CGS and non‐CGS for the most of the windows except for a window at *MS4A6A* (*R* ^2^ = 0.98) which is 165 kb from the top window at *MS4A4A* (*R* ^2 ^= 0.37). The attenuation of the significance level was also observed at the individual SNP level for the comparisons of the two types of SNPs in each window, noting that the *APOE* region did not contain any non‐CGSes (Table [S4](#acel12964-sup-0001){ref-type="supplementary-material"}).

###### 

Comparisons of the top windows containing CGSes versus non‐CGSes

  Chr   Start         End           Gene     P of window   *N* of variants   LD between CGS and non‐CGS (R^2^)              
  ----- ------------- ------------- -------- ------------- ----------------- ----------------------------------- --- ------ ------------------
  2     127,847,001   127,848,000   BIN1     1.27E−13      3.30E−05          2                                   2   0.01   (2.38E−05, 0.01)
  11    59,923,001    59,924,000    MS4A6A   2.66E−10      0.786             2                                   4   0.98   (8.73E−03, 0.98)
  11    60,087,501    60,088,500    MS4A4A   6.36E−10      0.029             2                                   9   0.37   (5.99E−04, 1)
  11    85,759,501    85,760,500    PICALM   6.34E−09      0.035             2                                   6   0.15   (1.33E−03, 0.24)
  19    45,411,501    45,412,500    APOE     2.99E−46      NA                2                                   0   NA     NA

John Wiley & Sons, Ltd

2.2. Association of CGSes with DNA methylation and gene expression {#acel12964-sec-0004}
------------------------------------------------------------------

Windows containing CGSes located in *MA4A4A*, *PICALM* and *APOE* were associated (*p* $\leq$ 0.05) with the degree of DNA methylation in brains (Table [4](#acel12964-tbl-0004){ref-type="table"}); however, only the *MS4A4A* window was significantly associated in brains after correction for the 176 methylation probes tested for association (adjusted *p* = 2.15 × 10^−9^ at cg14750746). This window was also nominally associated with increased methylation in blood after correcting for the same 176 methylation probes (nominal *p* = 3.34 × 10^−4^ and adjusted *p* = 0.06). In addition, the number of CpG dinucleotides created by the CGSes in the intergenic window between *MS4A4A* and *MS4A6E* was associated with increased expression of *MS4A4A* in both brain (*p* = 0.03) and blood (*p* = 2.53 × 10^−4^). The *MS4A6A* window was associated with DNA methylation (adjusted *p* = 1.47 × 10^−7^) and gene expression (*p* = 5.89 × 10^−26^) in blood, but rs12226022 was not well imputed in the ROSMAP dataset to test this association in brain.

###### 

Association between CGSes and methylation and gene expression

  Gene     Position      Name         Methylation of CpG site   Gene expression                                                                                                                             
  -------- ------------- ------------ ------------------------- ----------------- ---------- ---------- ---------------------- ---------- ---------- ----------------- ------ ------ ---------------------- ----------
  BIN1     127,800,646   cg00436254   −1.87E−04 (2.28E−03)      0.93              1.00       2.08E−03   −5.48E−03 (6.40E−04)   1.97E−17   5.56E−15   2.40 (2.27)       0.29   0.41   −8.40E−03 (4.15E−03)   0.04
  MS4A6A   59,824,541    cg01917716   NA                        NA                NA         NA         −2.91E−03 (4.72E−04)   8.13E−10   1.47E−07   NA                NA     NA     −0.04 (3.55E−03)       5.89E−26
  MS4A4A   60,101,475    cg14750746   5.60E−03 (8.11E−04)       1.22E−11          2.15E−09   0.03       −2.49E−03 (6.93E−04)   3.34E−04   0.06       0.14 (0.07)       0.03   0.07   0.09 (0.02)            2.53E−04
  PICALM   85,566,560    cg15822411   −3.42E−03 (1.77E−03)      0.05              1.00       1.00       −6.97E−04 (4.10E−04)   0.09       1.00       3.14E−03 (0.41)   0.99   0.76   7.68E−03 (5.11E−03)    0.13
  APOE     45,395,297    cg02613937   −9.96E−04 (4.19E−04)      0.02              1.00       0.42       −4.25E−03 (2.90E−03)   0.14       1.00       −2.93 (6.19)      0.64   0.60   6.94E−03 (6.13E−03)    0.26

Statistics obtained from CGSes dosage tests. *P*1 represents uncorrected *p*‐values, and *P*2 represents Bonferroni corrected *p*‐values calculated by multiplying the number of methylation probes included in the test which are within 1Mb distance to the window.

Statistics obtained from SKAT‐O tests.
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2.3. Pathway analysis at the *MS4A4A* window {#acel12964-sec-0005}
--------------------------------------------

Transcriptome analysis using RNAseq data from the Religious Order Study and Rush Memory and Aging Project (ROSMAP) brain samples was performed to identify the set of genes whose expression is influenced by methylation of CpG site cg14750746 that was associated with the dosage of *MS4A4A* CGSes (Table [4](#acel12964-tbl-0004){ref-type="table"}). In total, 15,508 protein‐coding genes remained in the analysis after removing genes expressed in less than 10% subjects. Although no genes remained significant after correcting for the number tests (threshold *p* = 3.2 × 10^−6^), there were 34 nominally associated genes (*p* \< 5×10^‐3^) (Table [S5](#acel12964-sup-0001){ref-type="supplementary-material"}) and pathway analysis showed enrichment in methyltransferase activity (Table [5](#acel12964-tbl-0005){ref-type="table"}).

###### 

Enrichment of methyltransferase activities in the regulatory network of MS4A cluster‐associated CpG site (cg14750746) in brain using Gene Ontology (GO) terms

  GO term ID   GO term description                                                                                                             P          FDR
  ------------ ------------------------------------------------------------------------------------------------------------------------------- ---------- ------
  GO:0050313   sulfur dioxygenase activity                                                                                                     8.31E−04   0.03
  GO:0008276   protein methyltransferase activity                                                                                              1.19E−03   0.03
  GO:0008170   N‐methyltransferase activity                                                                                                    1.23E−03   0.03
  GO:0070905   serine binding                                                                                                                  1.66E−03   0.03
  GO:0003713   transcription coactivator activity                                                                                              1.69E−03   0.03
  GO:0004843   ubiquitin‐specific protease activity                                                                                            2.44E−03   0.03
  GO:0042799   histone methyltransferase activity (H4‐K20 specific)                                                                            2.49E−03   0.03
  GO:0019783   ubiquitin‐like protein‐specific protease activity                                                                               2.95E−03   0.03
  GO:0036459   ubiquitinyl hydrolase activity                                                                                                  3.01E−03   0.03
  GO:0008234   cysteine‐type peptidase activity                                                                                                8.70E−03   0.06
  GO:0008139   nuclear localization sequence binding                                                                                           9.11E−03   0.06
  GO:0008168   methyltransferase activity                                                                                                      9.91E−03   0.06
  GO:0016741   transferase activity, transferring one‐carbon groups                                                                            0.01       0.06
  GO:0003756   protein disulfide isomerase activity                                                                                            0.02       0.08
  GO:0016864   intramolecular oxidoreductase activity, transposing S‐S bonds                                                                   0.02       0.08
  GO:0005096   GTPase activator activity                                                                                                       0.02       0.08
  GO:0016702   oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen   0.02       0.08
  GO:0016701   oxidoreductase activity, acting on single donors with incorporation of molecular oxygen                                         0.02       0.08
  GO:0030695   GTPase regulator activity                                                                                                       0.02       0.08
  GO:0005048   signal sequence binding                                                                                                         0.02       0.08
  GO:0060589   nucleoside‐triphosphatase regulator activity                                                                                    0.02       0.09
  GO:0018024   histone‐lysine N‐methyltransferase activity                                                                                     0.03       0.09
  GO:0016278   lysine N‐methyltransferase activity                                                                                             0.03       0.10
  GO:0016279   protein‐lysine N‐methyltransferase activity                                                                                     0.03       0.10
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3. DISCUSSION {#acel12964-sec-0006}
=============

Our study using a sliding‐window approach confirmed the importance of CGS in AD and is the first to report dosage effects of CpG dinucleotides created by CGSes on AD risk. In particular, we identified six windows with a significant effect of the number of CpG dinucleotides on AD risk, including a novel and robust dose‐dependent effect in an intergenic window located between *MS4A4A* and *MS4A6E*. The number of CpG dinucleotides created by the CGSes within this window is inversely associated with the risk of AD. The potential functional importance of CGSes in AD is supported by evidence showing that the significance of almost all of the top windows was attenuated when non‐CGSes were included instead of CGSes. This observation does not seem to be related to the differences in the number of variants or LD between CGSes and non‐CGSes.

The *MS4A* gene cluster encodes a family of proteins spanning the cellular membrane four times which share similar polypeptide sequence and predicted topological structure. *MS4A6A* expression in brain is positively associated with AD‐related neurofibrillary tangles and neuritic plaques (Karch et al., [2012](#acel12964-bib-0020){ref-type="ref"}; Martiskainen et al., [2015](#acel12964-bib-0027){ref-type="ref"}). AD risk alleles at these loci were reported to be associated with higher expression in brain (Allen et al., [2012](#acel12964-bib-0001){ref-type="ref"}; Karch et al., [2012](#acel12964-bib-0020){ref-type="ref"}; Martiskainen et al., [2015](#acel12964-bib-0027){ref-type="ref"}). The underlying mechanism for the effects of *MS4A* genes on AD may be related to their regulation of calcium channels (Walshe et al., [2008](#acel12964-bib-0038){ref-type="ref"}), immune system (Zuccolo et al., [2013](#acel12964-bib-0043){ref-type="ref"}). Our findings of an association of the CpG dinucleotide dosage in this region with AD risk suggest a potential novel AD‐related mechanism involving *MS4A* genes. Further experiments examining DNA methylation in the *MS4A* region are necessary to clarify the exact mechanism.

All of the loci identified in our study using a sliding‐window approach were previously reported to be associated with AD through DNA methylation analyses, indicating an overlap between genetic and epigenetic mechanisms. For example, brain DNA methylation levels of CpG sites located in the top‐ranked loci have been associated with clinical and pathological diagnoses of AD in a sample of 740 ROSMAP participants, many of whom are included in the ADGC GWAS dataset (De Jager et al., [2014](#acel12964-bib-0007){ref-type="ref"}). The mQTL CpG sites identified in our study are correlated with the previously reported (De Jager et al., [2014](#acel12964-bib-0007){ref-type="ref"}) AD‐associated CpG sites in both brain and blood (all *p* \< 0.05) (Table [S6](#acel12964-sup-0001){ref-type="supplementary-material"}), but it is unclear why the pairs of methylation probes in *MS4A* region and *APOE* are inversely correlated in brain and blood.

All of the genes identified by our analyses have been implicated in inflammation and the immune system. *BIN1* knock‐out mice were shown to have higher incidence of inflammation during aging (Chang et al., [2007](#acel12964-bib-0006){ref-type="ref"}). *BIN1* was also reported to be related to inflammation and immunity by its participation in the phagocytic pathway (Gold et al., [2004](#acel12964-bib-0012){ref-type="ref"}) and regulation of critical enzymes against pathogens (Muller, DuHadaway, Donover, Sutanto‐Ward, & Prendergast, [2005](#acel12964-bib-0029){ref-type="ref"}). Genes in the *MS4A* family have been shown to activate T cells and trigger production of inflammatory cytokines (Yan et al., [2013](#acel12964-bib-0040){ref-type="ref"}). Expression of *PICALM* was reduced in subjects who underwent gastric bypass surgery to reverse their pro‐inflammatory state of obesity (Ghanim et al., [2012](#acel12964-bib-0010){ref-type="ref"}), and *PICALM* overexpression in vitro was found to reduce the endosomal localization of the mannose‐6‐phosphate receptor (M6PR) which binds to the herpes virus (Brunetti, Dingwell, Wale, Graham, & Johnson, [1998](#acel12964-bib-0005){ref-type="ref"}). It is still controversial whether *APOE‐*ε4 causes anti‐ or pro‐inflammatory effects, but it is generally accepted that *APOE* is related to inflammation (Dorey, Chang, Liu, Yang, & Zhang, [2014](#acel12964-bib-0008){ref-type="ref"}). Our collective findings suggest that DNA methylation may be a molecular mechanism underlying aberrant inflammatory responses related to AD.

Our findings also suggest that the sliding‐window approach focused on CGSes is useful for identifying loci whose influence on disease risk may involve clinically relevant epigenetic mechanisms. In the large GWAS conducted by the International Genomics of Alzheimer\'s Project (Lambert et al., [2013](#acel12964-bib-0021){ref-type="ref"}), approximately 44% of the top AD‐associated SNPs are CGSes. However, not all of these CGSes were significantly associated with AD in our analysis (e.g., CGSes in *CR1, CD2AP*, and *CLU*; Table [S1](#acel12964-sup-0001){ref-type="supplementary-material"}). Interestingly, none of these three loci were reported to have significant brain methylation changes related to AD pathology (De Jager et al., [2014](#acel12964-bib-0007){ref-type="ref"}), indicating that their effects on AD may not involve DNA methylation.

Our study has several limitations. All the identified top windows for AD were previously reported loci associated with AD (Guerreiro et al., [2013](#acel12964-bib-0013){ref-type="ref"}; Jonsson et al., [2013](#acel12964-bib-0017){ref-type="ref"}; Lambert et al., [2013](#acel12964-bib-0021){ref-type="ref"}; Naj et al., [2011](#acel12964-bib-0030){ref-type="ref"}). This was expected because the samples of our and previously published GWAS are highly overlapping. However, our study ascribes potential function to some of these results, especially those occurring in noncoding regions. In order to identify the relative importance of the CGSes in the top windows compared to non‐CGSes, we performed conditional analysis adjusting for the top GWAS SNP. For all windows, the association signal for both the GWAS SNP and CpG dosage was attenuated when both were included in the model. In particular, for the intergenic window between *MS4A4A* and *MS4A6E*, the *p*‐values for both CpG dosage and the GWAS variant had similar reduction in significance (Table [S7](#acel12964-sup-0001){ref-type="supplementary-material"}). The squared correlation (*r* ^2^) between the GWAS variant and the CGS with the largest influence on the dosage effect in *MS4A4A* window is 0.56. Thus, it is not possible to conclude from the conditional analysis whether the GWAS variant, the window CpG dosage, or another variant in the region that is correlated with both of these markers, is responsible for the association. We did not remove CGSes in high LD, which may inflate the number of significant findings. However, some of these associations may be independent because multiple adjacent methylated CpG sites can serve as the platform for chromatin binding proteins that lead to changes in chromatin state (Bartke et al., [2010](#acel12964-bib-0002){ref-type="ref"}). Another concern is that despite experimental evidence suggesting an optimal window size of 1kb, it is unknown whether other window sizes may increase power. Also, our selection of the default weights of variants has bias toward rare variants. Finally, we observed that the CGS most significantly associated with AD risk also has significant mQTL and eQTL effects that survive regional multiple test correction but do not achieve genome‐wide significance.

In conclusion, we confirmed the importance of CGS in AD and the potential for creating a functional genetic score based on CpG dosage to predict disease risk. However, it is unknown whether these CGS signals act as causative mechanisms in AD progression. Further replication and mechanistic studies are necessary to validate these findings. Future genome‐wide mQTL and eQTL analyses may extend our findings.

4. EXPERIMENTAL PROCEDURES {#acel12964-sec-0007}
==========================

4.1. Genome‐wide association analysis of CGSes with AD {#acel12964-sec-0008}
------------------------------------------------------

### 4.1.1. CGS annotation {#acel12964-sec-0009}

CGSes were annotated as described previously (Ma et al., [2016](#acel12964-bib-0026){ref-type="ref"}). In brief, CGS information was retrieved by Galaxy (Goecks, Nekrutenko, Taylor, & Galaxy, [2010](#acel12964-bib-0011){ref-type="ref"}) from UCSC human genome browser based on SNP141 and human hg19 sequence data.

### 4.1.2. Discovery stage subjects {#acel12964-sec-0010}

The discovery stage included 12,181 unrelated cases and 12,601 controls from 22 cohorts with European ancestry participating in the Alzheimer\'s Disease Genetic Consortium (ADGC) (Table [S2](#acel12964-sup-0001){ref-type="supplementary-material"}). Characteristics of the ADC7 cohort are provided in the Appendix [S1](#acel12964-sup-0001){ref-type="supplementary-material"}, and details of other study cohorts were previously described (Jun et al., [2016](#acel12964-bib-0019){ref-type="ref"}; Lambert et al., [2013](#acel12964-bib-0021){ref-type="ref"}). Studies of the individual cohorts were approved by the appropriate Institutional Review Boards, and written informed consent for all subjects was provided on behalf of themselves or for substantially cognitively impaired subjects, by a caregiver, legal guardian, or other proxy.

4.2. Statistical analysis {#acel12964-sec-0011}
-------------------------

Details of SNP genotyping and quality control are described elsewhere (Jun et al., [2016](#acel12964-bib-0019){ref-type="ref"}; Lambert et al., [2013](#acel12964-bib-0021){ref-type="ref"}). SNP genotype imputation was performed using IMPUTE2 with reference haplotypes from the March 2012 release of 1,000 Genomes. Principal component (PC) analysis was conducted using the smartpca program in EIGENSOFT (Patterson, Price, & Reich, [2006](#acel12964-bib-0031){ref-type="ref"}; Price et al., [2006](#acel12964-bib-0032){ref-type="ref"}) to evaluate population substructure within each dataset. Association of AD risk with CGSes was tested using a sliding‐window approach (Tang, Feng, Sha, & Zhang, [2009](#acel12964-bib-0037){ref-type="ref"}). Windows spanning 1kb were constructed based on evidence suggesting that sequence variants within 1 kb can affect the methylation status of a gene (Lienert et al., [2011](#acel12964-bib-0024){ref-type="ref"}). Consecutive windows with a 500 bp overlap were tested to optimize power for detection of associations and ensure a sufficient number of SNPs in each window. Thus, for example, each unique 2000 bp region contains three overlapping windows. CGSes with imputation quality (*r* ^2^) ≤0.4 or genotype data available for less than half of the cohorts were removed. Windows with fewer than two CGSes were omitted from the analysis. After these filtering steps, 2,288,371 windows remained for association analyses.

The association of AD with the combined effects of multiple CGSes in each window on the risk of AD was evaluated by logistic regression using the optimal sequence kernel association test (SKAT‐O) (Lee et al., [2012](#acel12964-bib-0022){ref-type="ref"}) using R package seqMeta (<https://cran.r-project.org/web/packages/seqMeta/index.html>) as implemented in Universal Genome Analyst (UGA) software (<https://github.com/rmkoesterer/uga>). The fast *P* value calculation "integration" method was used as a screening tool. Windows with *p* ≤ 5 × 10^‐4^ or no reported *p* value were re‐analyzed using the "saddlepoint" method (Duchesne & de Micheaux, [2010](#acel12964-bib-0009){ref-type="ref"}). We used the default weights of the seqMeta package to up weight the contributions from rare variants with the aim to identify potential novel loci. The same methodology was applied to the analysis of non‐CGSes. SKAT‐O is not sensitive to effect direction of the individual variants included in the test and thus does not produce effect estimates. Thus, we also conducted the dose--response effect of the multiple CGSes in the window on AD risk using logistic regression. The allele that creates a CpG dinucleotide was considered as the effect allele and the allele that disrupts the CpG dinucleotide as the reference allele. The sum of the imputed dosages for multiple CGSes in each window was calculated and used as the exposure variable for the logistic regression model with AD status as the outcome. The summary statistics for regression coefficients and robust standard errors from each cohort were meta‐analyzed using an inverse variance‐weighted, fixed‐effects approach implemented in METAL (Willer, Li, & Abecasis, [2010](#acel12964-bib-0039){ref-type="ref"}). Both SKAT‐O and dosage analyses were adjusted for age, sex, and PCs. Windows surviving Bonferroni‐corrected genome‐wide significance level (*p* ≤ 5 × 10^−8^) from both methodologies were considered. The genome‐wide summary statistics from the two methodologies are provided in Table [S8](#acel12964-sup-0002){ref-type="supplementary-material"}.

### 4.2.1. Replication testing {#acel12964-sec-0012}

Cohort‐specific GWAS summary statistics were obtained from a prior AD GWAS conducted by the IGAP consortium, which includes 7,554 unrelated cases and 27,382 controls from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, the European Alzheimer\'s Disease Initiative (EADI), and the Genetic and Environmental Risk in Alzheimer\'s Disease (GERAD) consortium (Lambert et al., [2013](#acel12964-bib-0021){ref-type="ref"}). The protocols and participant consent forms were approved by each institution. The combined effects of multiple CGSes in each window on AD were determined using the GATES method, implemented in the GATES R package (Li, Gui, Kwan, & Sham, [2011](#acel12964-bib-0023){ref-type="ref"}). This method extends the Simes test to combine the *p*‐values of the SNPs within a region into an overall regional *p* value.

4.3. mQTL Analysis {#acel12964-sec-0013}
------------------

Brain mQTL was obtained for 740 subjects (mean age at death = 88 years, 63.6% female) from the Religious Order Study and Rush Memory and Aging Project (ROSMAP), and blood mQTL data obtained from 2,405 participants (mean age = 66 years, 54% female) of the Framingham Heart Study (FHS) Offspring cohort at examination 8 were downloaded from dbGAP (Table [S3](#acel12964-sup-0001){ref-type="supplementary-material"}). DNA methylation profiles for both studies were measured by the Illumina Infinium HumanMethylation450 BeadChip. Analyses of FHS data were conducted in two stages. A linear mixed model was used to derive the residuals of the DNA methylation of the probe adjusted for the imputed cell types (CD8T, CD4T, NK, B‐cell, monocyte), row and column as fixed‐effects, chip ID as a random effect at first. Then, each residual was regressed on the CGSes dosage in models including age and sex as fixed‐effects and kinship matrix as random effect to account for familial correlation. Analyses of ROSMAP data were conducted with the linear model by adjusting the methylation batch, age at death, sex, post‐mortem interval, and study group (ROS or MAP), which was test to be the most appropriate model for the data as reported by De Jager et al. ([2014](#acel12964-bib-0007){ref-type="ref"}). *p*‐values were adjusted using a Bonferroni correction for the total number of probes tested within each window.

4.4. eQTL analysis {#acel12964-sec-0014}
------------------

Brain RNAseq data were obtained for 580 ROSMAP subjects (mean age at death = 89 years, 63.3% female), and whole blood array‐based expression data for 5,252 FHS Offspring cohort (examination 8) and Generation 3 (examination 2) participants (mean age = 55 years, 54% female) were obtained from dbGAP (Supplementary Table [3](#acel12964-tbl-0003){ref-type="table"}). Normalized gene expression level was regressed on the sum of dosages of CpG dinucleotides in each window with covariates for age, sex, and the first three PCs of ancestry using a linear mixed model for analyses of FHS data and a general linear model for analyses of ROSMAP data. *p*‐Values were corrected for the seven tests (i.e., 7 genes) performed.

4.5. Pathway analysis {#acel12964-sec-0015}
---------------------

Using the ROSMAP brain methylation and RNAseq data, we performed a genome‐wide expression‐methylation scan using a general linear model with the methylation of CpG site cg14750476 as the exposure variable and the normalized gene expression levels of all the protein‐coding genes as outcomes (*n* = 15,508), including the same covariates as in the mQTL and eQTL analyses. Genes with *p* \< 0.005 were included in the pathway enrichment analysis implemented in the software of STRINGdb (Szklarczyk et al., [2015](#acel12964-bib-0036){ref-type="ref"}), which conducted a hypergeometric test, using the false discovery rate (FDR) to correct for multiple tests (Benjamini, [1995](#acel12964-bib-0004){ref-type="ref"}), to query the enrichment of the input gene sets against the background gene list in Gene Ontology database classified as "molecular function".
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